Kestra Medical Technologies (KMTS) Q3 2025 earnings summary

Executive summary

• Q3 FY2025 revenue reached $15.1 million, up 82% year-over-year, driven by 51% growth in prescriptions and expanding market share.

• Over 3,400 ASSURE system prescriptions in Q3, with active prescribing from more than 550 hospitals, representing 20% of U.S. WCD prescribing hospitals.

• Completed IPO in March 2025, raising between $205 million and $215.8 million in net proceeds, strengthening capital position for commercial expansion and operational investments.

• Expanded insurance coverage for ASSURE to over 285 million covered lives in the U.S., including Kaiser Permanente.

• Appointed Al Ford as Chief Commercial Officer and restructured organization.

Financial highlights

• Q3 FY2025 revenue was $15.1 million, up 82% year-over-year; nine-month revenue was $42.6 million, up 140%.

• Gross profit was $6.5 million in Q3, up from $0.9 million year-over-year; gross margin improved to 43.4% from 10.6%.

• Operating expenses rose to $27.1 million, reflecting commercial and revenue cycle headcount growth and $1.9 million in IPO-related costs.

• Net loss for Q3 was $21.8 million; nine-month net loss was $62.7 million, improved from $71.8 million prior year.

• Cash and equivalents totaled $54.4 million at quarter-end, excluding IPO proceeds.

Outlook and guidance

• FY2025 revenue expected between $58 million and $58.5 million, representing 109%–110% growth over FY2024.

• FY2026 guidance to be provided in July; focus remains on increasing in-network patient mix, expanding sales force, and improving revenue cycle management.

• Management expects existing cash, including IPO proceeds, to fund operations for at least the next 12 months.